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Summary.-This paper reports the findings of the M.R.C. study into the use of the
plasma CEA test for early detection of recurrence following "successful" surgery for
colorectal carcinoma. This study was set up in 1973, and represents the largest series
of patients published on this topic. It was primarily prospective, 468 patients being
entered at the time of, or after the initial diagnosis of colorectal carcinoma. Follow-
up was for at least2 years, and bothinitially and throughout thefollow-up the clinician
treating the patient was kept "blind" to the patient's plasma CEA level. The general
conclusion is that the CEA test provides a useful additional tool for the early detection
of recurrence in these patients. Sixty-five per cent of patients with recurrence showed
a raised plasma CEA level, and over half the patients who developed recurrence had
a raised level some time before the disease was detected by other means. A sur-
prising number of patients had a raised CEA level on a single occasion which subse-
quently returned to normal at the next follow-up and did not seem to be associated
with malignancy. The problems associated with this type of study and their limiting
effect on interpretation are discussed.
THIS STUIDY is one of a series initiated in
1973 by the Medical Research Council and
Health Department to investigate the
usefulness of plasma carcinoembryonic
antigen (CEA) in certain clinical situa-
tions. The primary aim of this study was
to examine a role for the CEA test for the
early detection of recurrence following
apparently successful surgery for colorec-
tal carcinoma. A recent, consensus state-
mnent (Br. lifed. J., 1981) on the use of the
CEA maintains that it is the best currently
available, non-invasive technique for the
surveillance of these patients, but no
guidelines are given to assist the cliniciain
with the interpretation of a single raised
CEAlevel. Thisstudyrepresents thelargest
published series of patients followed pros-
pectively; the information collected on
them has been used to evaluate the plasma
CEA test.
CLINICAL AND LABORATORY DATA
This was a multicentre study, and con-
secutive patients w%Nere entered from 15 hos-
pitals throughout the UJ.K. at the time of the
initial diagnosis of colorectal carcinoma (for
one centre there w%Nas available information
on patients who had undergone surgery some
time previously, but who were then followed
prospectively after entering the study).
Entry to the study started in 1973 and con-
tinued until 1976. The study closed at
followN-up in 1978, thereby allowNing a mini-
mum follow-up period of 2 years.
Only patients in whom surgery was con-
sidered at the time to have removed all
tumour wN-ere included (Dukes' D patients
were not included). A brief history was
recorded, and for some patients a pre-
operative plasma specimen w%Nas available for
CEA determination. The treatment was
recorded and Dukes' classification of the
tumour noted. The Biostatistics Unit wi-as
responsible for the overall coordination of theH. TATE
study, and the clinical details were recorded
on forms which were sent there. The plasma
specimens from all hospitals were sent to the
laboratory, where they were assayed by a
double-antibody radioimmunoassay system
(Laurence et al., 1972). The results of the
CEA assays were sent direct to the Bio-
statistics Unit. The clinician-in-charge of the
patients was not told the CEA result, and
therefore was not in a position to have his
attitude to the patient influenced by this
information. This "blindness" is absolutely
essential in a study of this nature, where the
aim is to assess the potential impact of an
additional test result. The study may be
likened to a clinical trial (each patient being
his own control) with the clinical progress of
the patients without the CEA test repre-
senting a control group (hence the blindness)
and a retrospective analysis with the CEA
result available as a test group.
The follow-up procedure for each patient
complied with the normal clinical practice
for the hospital concerned and, in addition,
at each follow-up examination a specimen of
plasma was taken for CEA determination.
The results ofthe examination were recorded
on a form sent to the Biostatistics Unit. The
plasma specimen wassenttothelaboratory for
assay, and the result then conveyed to the
Biostatistics Unit. Any concurrent disease
within the follow-up period and any addi-
tional treatment to the carcinoma or any
other condition was noted.
The clinical information and CEA levels
for each patient became available over time,
and these data were collated at the Bio-
statistics Unit. Extra information, in the
form of clinical details to clarify apparent
inconsistencies, and causes of death for those
known to have died but the cause was
not given by the centre, was sought, to
complement that received on the standard
forms.
In general, the follow-up data take the form
of a series of clinical pictures of each patient
over time, with a plasma CEA level associa-
ted with each ofthese. For each examination
the data have been reduced to the date ofthe
examination, and whether or not there was
suspicion of or definite evidence for malig-
nancy. Unfortunately it has not been possible
to separate local and metastatic disease, and
they have been considered as a single recur-
rence category. This is because a large prop-
ortion of patients had both local and meta-
static disease, and also because little de-
tailed information on the site of recur-
rence was available. Follow-up examinations
were seldom more frequent than every 6
months.
When analysing data of this type (i.e.
comparing information from follow-up exam-
inations with a single test result) it is essential
to remember that the follow-up examinations
varied considerably in terms of clinical
investigation and the type and number of
tests carried out. Also, the frequency of
examinations was not specified by the study
protocol and varied from centre to centre,
and between patients within a centre. The
outcome of this is that although CEA is
assessed against the "normal" backgrounds
of tests and examinations that actually took
place, in the analysis the inevitable grouping
of patients with different backgrounds can
lead to difficulties of interpretation.
The patients may be examined only briefly
or in depth, and it is necessary to consider
the consequences of this. If the patient
underwent a superficial examination only, it
is possible that there may have been evidence
of recurrence which was overlooked; a false-
negative clinical error may be made in that
the patient is declared free from disease when
disease is actually present and could have
been detected had other means been used. If
the patient underwent a thorough examina-
tion it is improbable that the reverse would
happen; i.e. that the clinician would say he
has detected recurrence when in reality the
patient is well. Of course, there may be
suspicion of recurrence, which may not be
confirmed, but a false positive clinical error
is highly unlikely.
Another feature of this study, which is
common to any investigation in which
patients are followed up with a certain end-
point in mind, is the existence of censoring;
i.e. the end-point of interest may not have
become apparent by the end of the follow-up
period. or some other event has prevented
its being observed (e.g. death from another
cause has meant that micrometastases in a
patient remained undetected). The magnitude
of the effect of censoring will depend on the
natural history of the disease in relation to
the length ofthe follow-up period. The length
offollow-up will vary from patient to patient,
as patients were diagnosed and entered the
study over a period of time and follow-up
ended on a given date. In this case the
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problem is not that the data may contain a
false-negative clinical classification, but that
a patient with a true negative classification
(i.e. the disease could not have been detected
by other means) at a given time, could
become one with a positive classification in
the future, and because follow-up finished,
this was not recorded. This is a particularly
pertinent point in this type of study, where
one is looking for "early warning" of recur-
rence by comparing the CEA level with the
current and future clinical state of the
patient.
RESULTS
Analysis
The method of analysis adopted here
involves the use ofa critical level for CEA.
Any value over the critical level is
regarded as being an indicator of the
presence of cancer. The data are scanned
for values above this level, and as
information is available on the fate ofeach
patient, an appraisal of the usefulness of
CEA can be made. This conventional
approach has the disadvantage that it does
not use all the information on both the
clinical and tumour marker sides available
up to a certain time. The CEA levels are
classified only as below or above a critical
level, and the information available on the
clinical side is summarized by classifying
the patients into general groups.
The accepted critical level for plasma
CEA in colorectal carcinoma for the
laboratory at which these assays were
performed is 40 ng/ml, though in general
any value over 20'ng/ml is considered
raised. Levels between 20 and 40 ng/ml are
known in patients with certain infections
and chronic conditions (Laurence et al.,
1972). The results reported here are based
on a critical level of 40 ng/ml (30 and
35 ng/ml were investigated as critical
levels on these data and the conclusion was
that there was no evidence to advocate
changing the recommended critical level).
Of the 520 patients treated by surgery
which at the time was considered to be
ablative, for 15 no follow-up information is
available and a further 34 had had signs of
malignancy at their first follow-up exam-
ination after surgery. These 34 were never
considered free ofdisease and are excluded
from further analysis. Three further
patients developed malignancies of other
sites during the follow-up period, and
these have also been excluded, leaving 468
patients with successful surgery who were
regarded as disease-free at the first follow-
up examination. About half of these were
entered into the study some time after the
original surgery. Altogether, there were 94
Dukes' A, 226 Dukes' B and 128 Dukes' C
patients (for 20, Dukes' classification was
not known).
It is helpful to divide these patients into
general groups on the basis of their pro-
gress during the follow-up. Each group is
then examined in more detail. The follow-
ing groups have been chosen:
(1) Patients showing some evidence of
recurrence (either definite or suspected)
during their follow-up in the study.
(2) Patients whose plasma CEA level
rose at some stage to above the critical
level (after patients in group (1) have been
excluded).
(3) Patients who did not have a
recurrence noted whilst followed-up, and
whose CEA levels remained low, who are
know to have died. It is possible that such
patients may have died of causes directly
relating to their colorectal malignancy. An
example of this type of patient is one who
does not attend regularly for follow-up
perhaps through infirmity, or one who has
moved to another area.
All other patients not included in the 3
groups described above had low CEA
levels andno evidence ofrecurrence during
the study period and, if death occurred,
the cause of death was not attributable to
colorectal malignancy. The 3 groups de-
scribedabove are examined in more detail.
Recurrence
There was some evidence of recurrence
during follow-up in 83 patients. In these
the recurrence was either suspected or
shown to be present by firmer evidence. In
some cases there was first a suspicion
which was later confirmed, whilst in others
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an initial suspicion was not confirmed and
the patients were considered later to be
free from disease. In some patients the first
indication of recurrence was definite. The
following 4 classifications summarize the
relationship found between plasma CEA
level and recurrent malignancy in the
patients:
(1) Prior warning.-For these patients
the plasma CEA value was raised above
the critical level at a follow-up examina-
tion before the one at which malignancy
was first detected (40 patients).
(2) Confirmatory increase.-Here the
CEA level was first raised at the same
examination (or a later one) as that at
which carcinoma was first detected (16
patients).
(3) No warning (D).-The detection of
definite recurrence was not preceded or
accompanied by an increase in plasma
CEA level (12 patients) (CEA is giving a
false-negative result).
(4) No warning (S).-There was no
increase in plasma CEA level in these
patients, but the carcinoma was only
suspected and, unlike (3), in no case
confirmed (15 patients).
The "prior warning" and "confirmatory
increase" groups have been subdivided
into 3: those whose disease was confirmed
while the paient was alive (which may
have been preceded by suspicion of
disease), those whose disease was sus-
pected only during follow-up but con-
firmed at death, and those whose disease
was suspected only, but remained uncon-
firmed. For the "confirmatory increase"
group there were 4 patients suspected of
recurrence on one occasion during follow-
up. At the subsequent follow-up examina-
tions, these patients were considered free
from disease. At the final examination
known to the study, these patients were
still considered free from disease, but on
this occasion the CEA was raised. These
patients, together with the 2 patients in
the "prior warning" group whose disease
remained unconfirmed, have been con-
sidered as free from recurrence in future
analysis.
Of the 15 patients in whom carcinoma
was suspected and not confirmed, who had
no increased CEA level ("no warning" (S)
group), 10 were followed for a considerable
time, with no further suspicion of malig-
nancy. For the other 5 the follow-up
examination at which malignancy was
suspected was the last one known to the
study. All 15 patients have been consid-
ered as disease-free in later analyses.
The results are discussed in detail later,
but it can be seen from Table I that in over
three-quarters (50/62) ofthese patients the
definite recurrence ofmalignancy is associ-
ated with a high plasma CEA level.
No recurrence and raised CEA values
The remaining 385 patients had no signs
during the study period of recurrent
malignancy, and may or may not have
died during this period. If they were
known to have died, the cause of death
was requested. The CEA levels of these
TABLE I. Patients with recurrence
Patient category
Prior warning
Confirmatory increase
No warning (D)
No warning (S)
Number ofpatients
Confirmed Confirmed at
during death, suspected
F-u during F-u I
31
12
7
0
12
Suspected only
during F-u,
not confirmed
2
4
15
CEA
category
Raised
>40
ng/ml)
Normal
(<40
ng/ml)
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patients have been scanned to pick out
any with high levels. Forty-six of these
patients had at least one level of 40 ng/ml
or more. The following 5 categories have
been chosen to help interpret data.
(1) Died, with malignancy.-The group
comprises patients who died of carcinoma
which was colorectal in origin although no
disease was detected atfollow-up examina-
tions. In fact, 11 ofthese 20 patients were
seen within 6 months.
(2) Died, other causes. There were 3
patients in this group. (There were no
deaths from malignancies of other sites in
this group.)
(3) Persistent high values.-One patient
had extremely high, increasing plasma
CEA values, but had no evidence of
malignancy at the time she moved and was
lost to follow-up.
(4) Spurious.-For these 16 patients
there was a single high value followed by a
least 1 low one.
(5) Final value high.-This group in-
cludes 6 patients whose only raised plasma
CEA value was their final one in the study.
Further clinical information was sought,
and for 4 of these there was no sign of
carcinoma for at least 3 years after the
high value.
The results are given in Table II. All
TABLE II.-Patients with no recurrence
duringfollow-up and raised CEA levels
Patient category
Died of CC
Died, other causes
Persistent high values
Spurious
Final value high
Total
Number ofpatients
with raised CEA
20
3
1
16
6
46
patients in this table, except those dying
of colorectal carcinoma, have been consid-
ered free of malignancy in later analyses.
Deaths of those with no recurrence
Finally, it is necessary to search through
the remaining patients (i.e. those with no
sign ofrecurrence during their follow-up in
the study, and whose plasma CEA levels
remained below 40 ng/ml) to ascertain the
causes of death for those who died. This is
important, as paients may have died
suddenly, of causes relating to the colorec-
tal malignancy, after having no indication
during the follow-up examinations and no
sign via a raised plasma CEA value. In
fact, of the 51 who died, 26 died of causes
directly related to colorectal carcinoma, 3
died of other malignancies not apparent
during follow-up, and 22 died of non-
malignant causes. Of the 26 dying of
colorectal carcinoma, 7 were examined
within 6 months of death and a further 6
were seen between 6 months and 1 year
before death; no recurrence was noted at
these examinations.
DISCUSSION
Of 468 patients treated by successful
surgery for colorectal carcinoma, and clear
from signs of malignancy at the first fol-
low-up examination, recurrence was con-
firmed during their lifetime in 55
(31 + 12+ 12 (all Table I)) and a further 53
(7 (Table I) +20 (Table II)+ 26) died of
colorectal malignancy. Of the 55, 31
showed prior warning of the confirmed
malignancy via a plasma CEA level
> 40 ng/ml. Of the 53 who died, 27 had a
raised CEA level sometime before death.
TABLE III.-Recurrence or deathfrom colorectal carcinoma (CC)
No. ofpatients with first
raised CEA and later
definite recurrence while
alive
No. ofpatients with first
raised CEA who later died
of CC
0-3 3-6 6 months- 1-2
months months 1 year years
3 7 9 10
5 0 8 9
23
>2
years Total
2 31
5 27
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Table III shows the number of these
patients against time before recurrence or
death when the plasma CEA level was first
raised.
The plasma CEA level was first raised
> 1 year before recurrence in 12 patients,
and > 1 year before death in 14. It was
raised in 2 patients >2 years before a
recurrence was detected and in 5> 2 years
before death.
A word of caution is called for in
examining these data, relating to their
nature and in particular to the pooling of
information on patients who had different
histories and who underwent different
follow-up schedules. For example, the
patients whose first raised CEA level was
within 3 months of the detection of
recurrence could comprise patients who:
(a) developed recurrence immediately
after the operation (after being clear of
signs of recurrence at the first follow-up);
(b) patients with very sporadic follow-
ups but seen within 3 months of a
recurrence being detected;
(c) patients with regular follow-ups, and
whose plasma CEA level remained "nor-
mal" until within 3 months ofa recurrence
being detected.
In fact, 1 patient belonged to category (a)
and 2 to category (c). However, it should
be noted that once the CEA level rises, in
patients with recurrence, it remains high.
Once a high CEA level has been noted in a
patient, there must always exist the
possibility that, had a CEA test been
carried out earlier, the level would have
been raised then also. This means that any
interpretation ofdata from a study such as
this, where follow-up was irregular, to the
effect that a CEA test is helpful, must be
considered relevant; i.e. in such a study,
CEA is given less chance to prove itself,
and therefore any indication that the CEA
test is useful, must be meaningful.
For the total of 468 patients, it is
possible to classify each as +ve or -ve to
the CEA test (patients with at least 1
raised CEA level being defined as +ve)
and also according to whether malignancy
TABLE IV.-CEA-test classification and
presence of CC
cc
CEA test
+
Total
+
70 32
38 328
108 360
Total
102
366
468
developed or not. Table IV shows the
resulting 2 x 2 classification. The data over
the whole ofthe time-span on each patient
are greatly simplified in this table, and as
stated previously there is a different
amount ofinformation on each patient. It
is worth noting here the scope for
misclassification. As mentioned previ-
ously, there is the possibility that a
malignancy may have been overlooked or
had not manifested itself to be detectable
at routine follow-up. If the CEA level for
such a patient were raised, this would be
classified as a false-positive CEA result.
Another obvious source of misclassifica-
tion concerns the 26 patients with always
low CEA levels, who died of colorectal
carcinoma. Twelve of these patients were
not examined (and no plasma sample
taken for CEA determination) for > 1 year
before death and 6 for > 2 years before
death. For these patients the CEA test is
showing a false-negative result, but if
further plasma specimens had been taken
before death. the picture may have been
different.
The strong association between a posi-
tive CEA result and colorectal malignancy
is apparent for each of the 3 Dukes' classi-
fications consideredseparately(A, BandC).
An estimate of the true positive rate of
the CEA test can be made; this is the
percentage of patients with malignancy
out of those who are positive to the test.
(The range in parentheses represents a
95% confidence interval.)
True positive rate=
70
102=69% (59-78)
This provides a guide to the interpretation
of a positive CEA result. The largest
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groups ofpatients who were positive to the
test but did not have malignancy are the
"spurious" group, i.e. those with a single
raised CEA value followed by lower ones.
There is some evidence that a high
preoperative CEA level may take some
time to return to normal, and that odd
single raised values may occur up to 6
months after surgery. However, only 7 out
of the 16 had a single high value within 6
months of surgery, and the remaining 9
had the spurious high value > 1 year after
the operation.
The true negative rate is also calculated:
3286=90% (86-93)
For completeness the sensitivity and
specificity ofthe test are given.
The sensitivity of a test is the propor-
tion ofthose with disease who are positive
to the test:
-70°%=65% (56-74)
The sensitivity of detection of the disease
before other evidence of recurrence can
also be calculated:
58 50 1508 = o (44-64)
In 54% of patients developing recurrence
or dying from their malignancy, there was
a raised CEA level some time before that
event, in almost halfofthese (26 out of58)
the plasma CEA level was raised a year or
more earlier.
The specificity ofa test is the proportion
of those without the disease who show a
negative reult. An estimate of this can be
made:
360=91% (88-94)
Of course, all the rates calculated above
refer to the use of CEA in the specific
clinical context of monitoring after sur-
gery and one clear follow-up examination
for colorectal carcinoma, and do not
apply to general-population screening for
disease.
CONCLUSIONS
The results from this study suggest that
the plasma CEA test is a useful additional
test for the detection of recurrence of
colorectal carcinoma. The accepted critical
value for the laboratory carrying out these
assays is 40 ng/ml and using this, 69% of
patients with a raised CEA level were
shown by other means to have malig-
nancy. There was prior warning of recur-
rences in 54% ofthose who relapsed and a
lead time > 1 year was evident in 24% of
cases. Of the 70 patients in whom
recurrence was noted (Table IV) for 54
there is available at least one further CEA
level after the first raised one. In 53 of
these, the subsequent CEA levels were also
raised; in most cases this was striking. The
general conclusion is therefore that once
the CEA level becomes elevated in
patients with recurrence it remains high
and often rises to extremely high levels.
The optimal use to which CEA can be
put is an important issue. Decreasing the
critical value to 30 ng/ml substantially
decreases the true-positive rate for the
test, as many more additional patients
without recurrence would be positive to
the test. The use of consecutive raised
values seems indicated, but unfortunately
the data from this study do not lend
themselves to a detailed analysis of this.
The often long interval between consec-
utive follow-ups mean that had this
approach been adopted no patient could
be designated as positive until the second
of 2 raised values. Tumour may be
detected by other means at the second
examination and this would mean for
these patients no prior warning via CEA.
It has been suggested that 2 consecutive
CEA values > 30 ng/ml may be the best
way of using this test. Certain observa-
tions regarding this approach can be made
from this study. It is to be expected that
2-3% of values from "normal" patients
would be > 30 ng/ml. Where CEA is raised
in patients with recurrent malignancy and
a series of values are available, in most
cases the CEA rises quickly and reaches
very high levels. For example, 39 patients
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with recurrence have values > 100 ng/ml,
and 15 ofthese reach values > 1000 ng/ml.
A value ofbetween 30 and 40 ng/ml could
be due to random variation in a patient in
the "normal" state, or the beginning ofan
increase in CEA level due to malignancy.
If CEA rises quickly and there is a long
period between follow-up examinations,
there would not be expected to be many
values in the range 30-40 which are due to
malignancy. This appears to be the case
withthese data. Ofthe 83 patients in Table
I, 17 had at least one CEA value of 30-40
at some stage during theirfollow-up. Eight
of these 17 had a plasma level of < 30 at
the next follow-up. These 8 values are
quite compatible with the number be-
tween 30 and 40 ng/ml which would be
expected to occur with chance variation in
normal patients. In 5 of these 8, a definite
recurrence was detected some time later
(in 4/5 cases the CEA levels became
greatly increased later in follow-up, after
returning to below 30 ng/ml). A further
study with more frequent testing of CEA
level is needed to determine the best way
of using serial CEA values.
The "spurious" single raised CEA levels
which returned to normal at the next
examination and did not appear to be
associated with malignancy again indicate
the need for further work. If an approach
involving two raised values is to be investi-
gated, the period between consecutive
readings could be chosen to ensure that
CEA is used in an optimal way. Some
current work, in fact, uses two consecutive
raised values as a definition ofraised CEA
level, to study the effect ofan intervention
programme, based on CEA, on the prog-
nosis for the type of patient considered
here (Ratcliffe et al., 1979). Other proposed
methods ofdetecting a significant increase
in CEA include the use of a nomogram to
compare the postoperative level with a
subsequent level (Martin et al., 1977) and
an approach using the rate of increase of
CEA in plasma (Staab et al., 1978).
The existence of false-negative results
also needs further investigation. These
occur in patients with malignancy whose
plasma CEA levels remain < 40 ng/ml. As
a general principle, to obtain the maxi-
mum amount ofinformation from a study
such as this, the protocol should define
strictly the set of tests and examinations
to be carried out. These should investigate
thoroughly the extent and location of any
disease. It may be found that further
facets of the disease (metastases in a
certain site, stage of differentiation of the
tumour, or rate oftumour growth) may be
associated particularly with increased
plasma levels ofCEA, and this information
would then be very valuable clinically.
Some in vitro work has suggested that the
output of CEA was inversely proportional
to the rate of cell division (Ellison et al.,
1977).
Various design problems associated with
this study have been mentioned where
they are relevant to interpreting the
findings. The experience gained from the
CEA studies in general should provide
sound guidelines for any similar project
(Tate, 1981).
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